Bailard, Inc. 89bio, Inc. Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
Shares
3 transactions
Others Institutions Holding ETNB
# of Institutions
175Shares Held
125MCall Options Held
84KPut Options Held
941K-
Janus Henderson Group PLC London, X016.5MShares$175 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$150 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$108 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$79 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$74.2 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $491M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...